GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Market Cap

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Market Cap : $0.07 Mil (As of May. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Clarus Therapeutics Holdings's share price for the quarter that ended in Jun. 2022 was $0.3821. Clarus Therapeutics Holdings's Shares Outstanding (EOP) for the quarter that ended in Jun. 2022 was 52.02 Mil. Therefore, Clarus Therapeutics Holdings's market cap for the quarter that ended in Jun. 2022 was $19.88 Mil.

Clarus Therapeutics Holdings's quarterly market cap declined from Dec. 2021 ($58.38 Mil) to Mar. 2022 ($36.88 Mil) and declined from Mar. 2022 ($36.88 Mil) to Jun. 2022 ($19.88 Mil).

Clarus Therapeutics Holdings's annual market cap stayed the same from . 20 ($0.00 Mil) to Dec. 2020 ($0.00 Mil) but then increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($58.38 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Clarus Therapeutics Holdings's Enterprise Value for Today is $21.41 Mil.


Clarus Therapeutics Holdings Market Cap Historical Data

The historical data trend for Clarus Therapeutics Holdings's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Market Cap Chart

Clarus Therapeutics Holdings Annual Data
Trend Dec20 Dec21
Market Cap
- 58.38

Clarus Therapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Market Cap Get a 7-Day Free Trial - 115.80 58.38 36.88 19.88

Competitive Comparison of Clarus Therapeutics Holdings's Market Cap

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarus Therapeutics Holdings's Market Cap Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Market Cap distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Market Cap falls into.



Clarus Therapeutics Holdings Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Clarus Therapeutics Holdings's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as

Market Cap (A: Dec. 2021 )=Share Price (A: Dec. 2021 )*Shares Outstanding (EOP) (A: Dec. 2021 )
=$2.43*24.0258
=$58.38

Clarus Therapeutics Holdings's Market Cap for the quarter that ended in Jun. 2022 is calculated as

Market Cap (Q: Jun. 2022 )=Share Price (Q: Jun. 2022 )*Shares Outstanding (EOP) (Q: Jun. 2022 )
=$0.3821*52.0207
=$19.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarus Therapeutics Holdings  (OTCPK:CRXTQ) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Clarus Therapeutics Holdings Market Cap Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
Thomas Mcnerney & Partners Lp 10 percent owner 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr director C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory director C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley director, officer: Chief Executive Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson officer: Chief Financial Officer 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger officer: Chief Commercial Officer CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne officer: Chief Administrative Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd 10 percent owner DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines

From GuruFocus